| Literature DB >> 36118026 |
Mengfan Jiao1,2, Xiaoxu Ma3, Yaoguang Li1,2, Huifen Wang1,2, Ying Liu1,2, Wenhu Guo4, Jun Lv1.
Abstract
Nocardia is an opportunistic pathogen that mainly involves immunosuppressed patients and causes a high mortality rate. As an emerging approach to detect infectious pathogens, metagenomic next-generation sequencing (mNGS) was reported in the detection of Nocardia. However, there is no evidence demonstrating the effect of mNGS on the prognosis of Nocardia infection. In this retrospective study, we included 18 nocardiosis patients. Nocardia species were detected by mNGS from their clinical samples. All the patients were diagnosed with nocardiosis by clinical experts through a comprehensive evaluation. Of these 18 patients, fever is the most frequent initial symptom. Compared to traditional culture methods, mNGS provides a faster turnaround time (TAT) and higher sensitivity. Pulmonary nocardiosis was the most common clinical presentation in the study. mNGS detected 13 types of Nocardia species, of which Nocardia abscessus and Nocardia cyriacigeorgica were the most common species. The study's most noteworthy discovery is that mNGS outperforms culture at detecting mixed infections (more than one pathogen detected in one clinical specimen, including bacteria, fungi, and excluding virus), and number of infectious species was an independent risk factor for nocardiosis patients' prognostics after adjusting age, ICU days, gender and underlying diseases (adjusted HR = 1.47, 95% CI: 1.09-1.98, p = 0.011). As a result, we believe that by detecting mixed infections (more than one pathogenic species), mNGS can provide a clinical risk warning for the prognosis of nocardiosis.Entities:
Keywords: Nocardia; infectious diseases; metagenomic next-generation sequencing (mNGS); mixed infection; precise treatment
Mesh:
Year: 2022 PMID: 36118026 PMCID: PMC9471186 DOI: 10.3389/fcimb.2022.894678
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Patients’ characteristics.
| Characteristics | Total (n=18) |
|---|---|
|
| 56.78 ± 14.19 |
|
| |
| Male | 14 (77.78) |
| Female | 4 (22.22) |
|
| 10 (55.56) |
| ICU days | 10.20 ± 8.32 |
|
| 6 (33.33) |
| Ventilator hours | 180.67 ± 77.18 |
|
| |
| <10 days | 5 (27.78) |
| 10-30days | 6 (33.33) |
| >30days | 7 (38.89) |
|
| |
| Fever | 13 (72.22) |
| Cough | 5 (27.78) |
| Chest tightness | 5 (27.78) |
| Chest pain | 3 (16.67) |
| Dyspnea | 2 (11.11) |
| Local swelling | 1 (5.56) |
|
| |
| Hypertension | 5 (27.78) |
| Diabetes | 5 (27.78) |
| Pulmonary disease | 5 (27.78) |
| CKD | 4 (22.22) |
| Coronary heart diseases | 3 (16.67) |
| Hepatitis C | 2 (11.11) |
| Malignant tumor | 1 (5.56) |
|
| |
| Pulmonary | 11 (61.11) |
| Disseminated | 5 (27.78) |
| CNS | 2 (11.11) |
ICU, intensive care unit; CKD, chronic kidney disease; CNS, central nervous system.
mNGS and microbiological culture information.
| Characteristics | Total (n=18) | P value |
|---|---|---|
|
|
| |
| BALF | 10 (55.56) | |
| Blood | 4 (22.22) | |
| CSF | 2 (11.11) | |
| Lung tissue | 1 (5.56) | |
| Abscess | 1 (5.56) | |
|
| 3.33 ± 4.21 | |
|
| 1.33 ± 0.77 | 0.001 |
|
| 2.78 ± 1.35 | |
|
| 4.67 ± 4.12 | 0.372 |
|
| 6.06 ± 5.05 |
CSF, Cerebrospinal Fluid.
Figure 1(A), infection types of the patients. (B), the frequency of the 13 Nocardia species detected by mNGS. (C), the distribution of Nocardia species in BALF, blood, and CSF samples. (D), overall survival analysis for nocardiosis patients according to infection types.
The comparison of characteristics between survivors and non-survivors.
| Feature | Survivors (n=11) | Non-survivors (n=7) | P value |
|---|---|---|---|
|
| 51.818 (15.728) | 64.571 (6.503) | 0.07 |
|
| |||
| female | 2 | 2 | 1 |
| male | 9 | 5 | |
|
| |||
| no | 2 | 1 | 1 |
| yes | 9 | 6 | |
|
| 1.818 (0.982) | 2 (1.633) | 1 |
|
| 1.273 (0.467) | 4 (3.464) | 0.006 |
|
| |||
| pulmonary | 6 | 5 | 0.793 |
| disseminated | 4 | 1 | |
| CNS | 1 | 1 | |
|
| 28.182 (13.659) | 20.571 (22.53) | 0.123 |
|
| |||
| no | 8 | 0 | 0.004 |
| yes | 3 | 7 | |
|
| 14.333 (15.695) | 8.429 (3.101) | 0.908 |
|
| |||
| no | 11 | 1 | 0 |
| yes | 0 | 6 | |
|
| |||
| mNGS turnaround time day | 1.364 (0.924) | 1.286 (0.488) | 0.755 |
| mNGS result time day | 5.818 (4.956) | 2.857 (0.9) | 0.23 |
| Specimen time | 4.455 (5.145) | 1.571 (0.535) | 0.509 |
| Culture turnaround time day | 2.909 (1.446) | 2.571 (1.272) | 0.737 |
| Culture result time day | 7.364 (6.12) | 4 (1.291) | 0.265 |
|
| |||
| Hospital costs | 0.573 (1.035) | 0.559 (0.284) | 0.085 |
| Antibiotic costs | 0.679 (0.861) | 0.554 (0.629) | 0.659 |
| Antibiotics percentage | 0.179 (0.074) | 0.119 (0.078) | 0.211 |
| Daily hospital costs | 0.468 (0.512) | 1.158 (0.655) | 0.035 |
| Daily antibiotic costs | 0.683 (0.504) | 1.012 (0.6) | 0.285 |
|
| 36.2 (42.949) | 71 (53.432) | 0.094 |
|
| 42.1 (42.969) | 72.2 (52.926) | 0.198 |
|
| |||
| no | 1 | 2 | 0.528 |
| yes | 10 | 5 | |
|
| |||
| CRP | 133.824 (107.458) | 139.841 (93.304) | 0.813 |
| PCT | 0.552 (0.422) | 4.201 (8.193) | 0.299 |
| ESR | 57.25 (27.366) | 80.6 (41.065) | 0.413 |
| Leukocyte | 13.432 (6.018) | 14.169 (6.753) | 1 |
CNS, central nervous system; ICU, intensive care unit, CKD, chronic kidney disease; mNGS, metagenomic next-generation sequencing; TMP-SMX, trimethoprim-sulfamethoxazole; CRP, C-response protein; PCT, procalcitonin.
Univariate analysis and multivariate analysis of overall survival in nocardiosis patients.
| Characteristics | Univariate analyses | Multivariate analyses | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
|
| 1.07 | 0.99-1.16 | 0.098 | 1.07 | 0.96-1.19 | 0.239 |
|
| 0.45 | 0.09-2.35 | 0.343 | 0.32 | 0.04-2.78 | 0.299 |
|
| 1.03 | 0.97-1.1 | 0.329 | 1.04 | 0.93-1.16 | 0.488 |
|
| 1.34 | 1.07-1.69 | 0.013 | 1.47 | 1.09-1.98 | 0.011 |
|
| 1.33 | 0.16-11.16 | 0.793 | 0.42 | 0.04-5.03 | 0.496 |
HR, hazard ratio; CI, confidence interval.